iBio (IBIO) investor relations material

Executive summary

• Focused on AI-driven discovery and development of precision antibodies for obesity and cardiometabolic diseases, with all therapeutics in preclinical stages and no clinical trials completed to date.

• Strategic shift toward IBIO-610, a long-acting antibody targeting Activin E, with first human clinical trials anticipated in early 2027; promising non-human primate data supports twice-yearly dosing for obesity.

• Recent collaboration and exclusive licensing agreements with AstralBio for myostatin (IBIO-600) and Activin E (IBIO-610) programs.

• Cash position strengthened with a $50 million underwritten public offering in August 2025, extending operational runway into Q4 FY2027.

• Regained compliance with Nasdaq Listing Rule 5550(a)(2) as of November 4, 2025.

Financial highlights

• Revenue of $0.1 million recognized for services to a collaborative partner in Q1 FY26; no revenue in prior year period.

• Net loss of $5.7 million for the quarter ended September 30, 2025, compared to $4.0 million in the prior year.

• R&D expenses increased to $3.6 million (from $1.3 million), mainly due to higher spending on consultants and advancing pipeline assets.

• G&A expenses decreased to $2.5 million (from $2.8 million), reflecting lower accounting, consulting, and legal fees.

• Cash, cash equivalents, and investments in debt securities totaled $49.6 million as of September 30, 2025.

Outlook and guidance

• Cash resources expected to support operations for at least 12 months from the filing date and into Q4 FY2027.

• No significant revenue expected for several years; future profitability depends on successful development, approval, and commercialization of product candidates.

• Ongoing efforts to seek development partners and out-licensing opportunities for pipeline assets.

• Focus remains on advancing IBIO-610 and broader pipeline for cardiometabolic and obesity diseases.